Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Cecilia Vold"'
Autor:
Jon R. Florholmen, Kay-Martin Johnsen, Renate Meyer, Trine Olsen, Øystein K. Moe, Petter Tandberg, Mona D. Gundersen, Jan-Magnus Kvamme, Knut Johnsen, Terje Løitegård, Gabriele Raschpichler, Cecilia Vold, Sveinung W. Sørbye, Rasmus Goll
Publikováno v:
BMC Gastroenterology, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background There are no accurate markers that can predict clinical outcome in ulcerative colitis at time of diagnosis. The aim of this study was to explore a comprehensive data set to identify and validate predictors of clinical outcome in t
Externí odkaz:
https://doaj.org/article/9177c6b0487643b7b2d2feb0352a80cd
Autor:
E. K. Strand, I. S. H. Hatten, Kathrine A. Seeberg, Knut E.A. Lundin, Rolf Anton Klaasen, Tore K Kvien, Knut Tveit, C. Mørk, Espen A Haavardsholm, S. S. Hoie, G. L. Goll, Gert Huppertz-Hauss, Jon Hagfors, A. Poyan, Synøve Kalstad, B. Gulbrandsen, Geir Noraberg, Jørgen Jahnsen, David J. Warren, K. Waksvik, K. Ryggen, H. U. Rashid, Cecilia Vold, Ingrid Prytz Berset, Øivind Asak, Nils Bolstad, S. O. Frigstad, Bjørg Tilde Svanes Fevang, Bjørn Moum, Ulf Prestegård, Joseph Sexton, C. C. Zettel, I. P. Midtgard, Magne Henriksen, Ingrid M. Blomgren, M. Lorentzen, Roald Torp, Carl Magnus Ystrøm, K. Skjetne, T. J. Bruun, Katrine Dvergsnes, Pawel Mielnik, J. Krogh, Ø. Brenna, Inge C. Olsen, Inger Marie Jensen Hansen, S. Baigh, K. K. Jørgensen
Publikováno v:
Journal of Internal Medicine
BACKGROUND AND OBJECTIVES: The 52-week, randomized, double-blind, noninferiority, government-funded NOR-SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT-P13 was not inferior to continued treatment wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed2e54f175da6e1a1bd891ec3eb52816
https://doi.org/10.1111/joim.12880
https://doi.org/10.1111/joim.12880
Autor:
Terje Løitegård, Jon Florholmen, Jan-Magnus Kvamme, Øystein Kittel Moe, Trine Olsen, Rasmus Goll, Cecilia Vold, Kay-Martin Johnsen, Mona Dixon Gundersen, Petter Tandberg, Gabriele Raschpichler, Knut Johnsen, Sveinung Wergeland Sørbye, Renate Meyer
Publikováno v:
BMC Gastroenterology, Vol 20, Iss 1, Pp 1-9 (2020)
BMC Gastroenterology
BMC Gastroenterology
Background There are no accurate markers that can predict clinical outcome in ulcerative colitis at time of diagnosis. The aim of this study was to explore a comprehensive data set to identify and validate predictors of clinical outcome in the first
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc33be21f597ac47913d3b06fd8a0588
https://doi.org/10.1186/s12876-020-01447-0
https://doi.org/10.1186/s12876-020-01447-0
Autor:
Øivind Asak, Nils Bolstad, Jon Florholmen, Jørgen Jahnsen, Inge C. Olsen, G. L. Goll, Kathrine A. Seeberg, Liv Sagatun, Geir Noraberg, Knut E.A. Lundin, David J. Warren, Cecilia Vold, Magne Henriksen, Ulf Prestegård, Joseph Sexton, Jon Hagfors, Jan Henrik Rydning, Ingrid M. Blomgren, Rolf Anton Klaasen, Katrine Dvergsnes, Kristin Kaasen Jørgensen, Carl Magnus Ystrøm, Tore K Kvien, Gert Huppertz-Hauss, Bjørn Moum, Ingrid Prytz Berset, Roald Torp, Svein Oskar Frigstad, Espen A Haavardsholm
Publikováno v:
BioDrugs
Biodrugs
Biodrugs
Background: TNF-alpha inhibitors have improved treatment of chronic immune-mediated inflammatory disorders. The NOR-SWITCH main and extension trial addressed switching from infliximab originator (IFX) to CT-P13 across six diseases. Here we present th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9abe8284e6a86f126777aa9b144edd9a
https://hdl.handle.net/11250/2683922
https://hdl.handle.net/11250/2683922
Autor:
Pawel Mielnik, Jørgen Jahnsen, Ingvild S H Hatten, Cecilia Vold, Maud-Kristine A Ljoså, Ulf Prestegård, Jon Florholmen, Magne Henriksen, Bjørn Gulbrandsen, G. L. Goll, Kåre S Tveit, Ingrid Prytz Berset, Ingrid M. Blomgren, Hilde Stray, Julia R Kruse, Sigrun K Sæther, Inger M Hansen, Somyeh Baigh, Katrine Dvergsnes, Kenneth Waksvik, C. Mørk, Bjørg Ts Fevang, Clara Gram Gjesdal, Gert Huppertz-Hauss, Inge C. Olsen, Nils J Mørk, Sunniva S Hoie, Jon Hagfors, Jan Henrik Rydning, Tore K Kvien, Kristine Skjetne, Njaal Stray, Kristin Ryggen, Synøve Kalstad, M. Lorentzen, David J. Warren, Geir Noraberg, Berit H J Grandaunet, Roald Torp, Bjørn Moum, Karoline J. Henanger, Armin Poyan, Svein Oskar Frigstad, E. K. Strand, Espen A Haavardsholm, Knut E.A. Lundin, K. K. Jørgensen, Camilla C Zettel, Jan Krogh, Irina P Midtgard, Øivind Asak, Trude J Bruun, Nils Bolstad, Haroon U Rashid, Kathrine A. Seeberg, Liv Sagatun, Carl Magnus Ystrøm
Publikováno v:
The Lancet. 389:2304-2316
Summary Background TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but are expensive therapies. The aim of NOR-SWITCH was to ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8cbbaec9dc7fa5b87aea27da7ee6159
https://doi.org/10.1016/s0140-6736(17)30068-5
https://doi.org/10.1016/s0140-6736(17)30068-5